Guardant Health is undervalued, making it a good time to accumulate more holdings. The company's positive future outlook isn't fully reflected in the current share price. Consider financial health before investing.
The recent share price drop may indicate unresolved challenges, despite the company's revenue growth. Investors are advised to ensure they are buying a high-quality business, even when the share price is low.
Guardant Health's high P/S ratio is due to strong revenue performance and promising future growth rates, bolstering shareholder confidence. Given the optimism, a significant stock price drop is unlikely soon.
Substantial insider acquisitions point to optimism for the company's prospects. However, the recent sale by the CIO may suggest some insiders think shares are overvalued. Still, high insider ownership implies alignment of management's interests with shareholders.
Wolfe Research Downgrades$Snowflake(SNOW.US)$to Peer Perform From Outperform Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ. Guggenheim Downgrades$MongoDB(MDB.US)$to Sell From Neutral, Adjusts Price Target to $210 From $205 MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
Gapping up $Adobe(ADBE.US)$+4.6%(The software company reported better-than-expected quarterly earnings and revenue that was in line with analyst forecasts. Adobe also issued upbeat current quarter guidance.) $達登飯店(DRI.US)$+1% (The parent of Olive Garden and other restaurant chains reported for its latest quarter, and exceeded analyst forecasts for same-restaurant sales. Darden also raised the lower end of its 2023 ea...
Guardant Health股票討論區
專欄US Top Rating Updates on 5/26: SNOW, MDB, UNH, GH and More
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US)$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
專欄Today's Pre-Market Stock Movers: ADBE, META, ACN, MAXR and More
$Adobe(ADBE.US)$ +4.6%(The software company reported better-than-expected quarterly earnings and revenue that was in line with analyst forecasts. Adobe also issued upbeat current quarter guidance.)
$達登飯店(DRI.US)$ +1% (The parent of Olive Garden and other restaurant chains reported for its latest quarter, and exceeded analyst forecasts for same-restaurant sales. Darden also raised the lower end of its 2023 ea...
What with this ? Too oversold
專欄Today's pre-market stock movers: PLTR, BBBY, BNTX, GOLD and more
In reaction to earnings/guidance:
• $Karuna Therapeutics(KRTX.US)$ +42.6% (also reports topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT), $monday.com(MNDY.US)$ +15.1%,$W&T海底鑽探(WTI.US)$ +6.7%,$HF Sinclair(DINO.US)$ +5.3%,$Viatris(VTRS.US)$ +4.3%,$Kosmos Energy(KOS.US)$ + 3.2%,$Holly Energy(HEP.US)$ +3.2%,$巴里克黃金(GOLD.US)$ +2.9%,...
專欄Top upgrades and downgrades on 6/3
• $Ciena(CIEN.US)$: B.Riley Upgrades to Buy from Neutral - PT $67 (from $65)
• $藝康集團(ECL.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $195 (from $180)
• $Hersha Hospitality Trust(HT.US)$: Jefferies Upgrades to Buy from Neutral - PT $13 (from $11)
• $馬丁-瑪麗埃塔材料(MLM.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $410 (from $420)
• $波特蘭通用電氣(POR.US)$: Goldman Sachs Upgrades to Buy from Neutral - P...
暫無評論